AR070540A1 - Derivados de 6-oxo-5, 6-dihidro-benzo[c][1, 8]naftiridina, un proceso para su preparacion, un kit que los incluye y su uso en la fabricacion de medicamentos para el tratamiento del cancer. - Google Patents
Derivados de 6-oxo-5, 6-dihidro-benzo[c][1, 8]naftiridina, un proceso para su preparacion, un kit que los incluye y su uso en la fabricacion de medicamentos para el tratamiento del cancer.Info
- Publication number
- AR070540A1 AR070540A1 ARP090100694A ARP090100694A AR070540A1 AR 070540 A1 AR070540 A1 AR 070540A1 AR P090100694 A ARP090100694 A AR P090100694A AR P090100694 A ARP090100694 A AR P090100694A AR 070540 A1 AR070540 A1 AR 070540A1
- Authority
- AR
- Argentina
- Prior art keywords
- het
- alq
- hal
- indicates
- nhet
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se describen compuestos derivados de benzonaftiridinilo y análogos de los mismos, y procesos para preparar los mismos. Los compuestos son utiles en el tratamiento de enfermedades sensibles a la inhibicion, regulacion o modulacion de la transduccion de senales de cinasas. Reivindicacion 1: Un compuesto de acuerdo con la formula (1) en donde W se selecciona de Hal, Ar-alq, Het-alq, O, OH, SH, S(O)mZ, S(O)mAr, S(O)mHet, Z, OZ, OAr, OHet, OAlq o NRR'; Q es N o NH para satisfacer la valencia adecuada X se selecciona de N o [N+-O-]; ------- indica un enlace sencillo o doble; R1, R2, R3, R4, R5 y R6 se seleccionan independientemente de hidrogeno, Hal, Z, OZ, OAr, OHet, OH, NRR', Ar, Ar-alq, Het, Het-alq, S(O)mZ, S(O)mAr, S(O)mHet, C(O)mOR, NRC(O)mR', NRSO2R', NRC(O)mNR', (CH2)nOZ o C(O)NRR'; R y R' se seleccionan independientemente de hidrogeno, Z, Ar, Ar-alq, Het, Het-alq, OZ, OAr, S(O)mZ, S(O)mAr o S(O)mHet; Z indica alquilo ramificado o no ramificado C1-10, en la cual 1-7 átomos de H se pueden reemplazar por F, Cl y/o Br, y/o en la cual uno o dos grupos CH2 no adyacentes se pueden reemplazar por grupos O, N, NH, S, SO, SO2, y/o CH=CH, o alquilo cíclico C3-7; Ar indica fenilo, naftilo o bifenilo, cada uno de los cuales es no sustituido o mono-, di- o trisustituido por Hal, Z, OR, N(R)2, SR, NO2, CN, COOR, CON(R)2, NRCOZ, NRSO2Z, SO2N(R)2, S(O)mZ, CO-Het, Het, O[C(R)2]nN(R), O[C(R)2]nHet, NHCOOZ, NHCON(R)2, NHCOO[C(R)2]nN(R)2, NHCOO[C(R)2]pHet, NHCONH[C(R)2]nN(R)2, NHCONH[C(R)2]pHet, OCONH[C(R)2]nN(R)2, OCONH[C(R)2]nHet, CHO y/o COZ; Hal indica Cl, Br, I o F; Het indica independientemente un heterociclo mono-, bi- o tricíclico saturado, no saturado o aromático que tiene 1 a 4 átomos de N, O y/o S; que puede ser no sustituido o mono-, di- o trisustituido por Hal, Z, OR, (CH2)pN( R)2, SR, NO2, CN, COOR, CON(R)2, O[C(R)2]nN(R), O[C(R)2]nHet1, NHCOOZ, NHCON(R)2, NHCOO[C(R)2]nN(R)2, NHCOO[C(R)2]nHet, NHCONH[C(R)2]nN(R)2, NHCONH[C(R)2]nHet, OCONH[C(R)2]nN(R)2, OCONH[C(R)2]nHet, NRCOZ, NRSO2Z, SO2N(R)2, S(O)mZ, CO-Het, CHO, COZ, =S, =NH, =NZ, oxi (-O-) y/o =O (oxígeno de carbonilo); alq indica alquileno ramificado o no ramificado C1-10, en el cual 1-7 átomos de H se pueden reemplazar por F, Cl, y/o Br, y/o en el cual uno o dos grupos CH2 no adyacentes se pueden reemplazar por grupos O, S, SO, SO2, NH, NZ, CH=CH y/o C:::C, y que se pueden sustituir por Hal, OR, SR, Ar y/o =O; m es 0, 1 o 2; n es 0, 1, 2, 3, 4, 5 o 6; p es 0, 1, 2, 3 o 4, y en donde al menos uno de R1 a R6 no es H, y un profármaco, derivado, solvato, sal, tautomero y estereoisomero farmacéuticamente aceptable del mismo, incluyendo mezclas de los mismos en todas las proporciones.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6749208P | 2008-02-28 | 2008-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR070540A1 true AR070540A1 (es) | 2010-04-14 |
Family
ID=40622992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090100694A AR070540A1 (es) | 2008-02-28 | 2009-02-27 | Derivados de 6-oxo-5, 6-dihidro-benzo[c][1, 8]naftiridina, un proceso para su preparacion, un kit que los incluye y su uso en la fabricacion de medicamentos para el tratamiento del cancer. |
Country Status (10)
Country | Link |
---|---|
US (1) | US8735584B2 (es) |
EP (1) | EP2254889B1 (es) |
JP (1) | JP5529761B2 (es) |
CN (1) | CN101952287B (es) |
AR (1) | AR070540A1 (es) |
AU (1) | AU2009219376B2 (es) |
CA (1) | CA2712990C (es) |
ES (1) | ES2401550T3 (es) |
IL (1) | IL207415A (es) |
WO (1) | WO2009108670A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009333653B2 (en) * | 2008-12-17 | 2015-09-10 | Merck Patent Gmbh | C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof |
EP2485589A4 (en) * | 2009-09-04 | 2013-02-06 | Biogen Idec Inc | HETEROARYARY INHIBITORS OF BTK |
EP2423208A1 (en) * | 2010-08-28 | 2012-02-29 | Lead Discovery Center GmbH | Pharmaceutically active compounds as Axl inhibitors |
GB2486631A (en) * | 2010-12-01 | 2012-06-27 | Univ Sheffield | Phenol/quinone boronic acids/esters and method of preparation thereof |
ES2590778T3 (es) | 2011-02-28 | 2016-11-23 | Calitor Sciences, Llc | Compuestos de quinolina sustituida |
MY185051A (en) * | 2011-03-08 | 2021-04-30 | Basf Se | Method for the preparation primary amines by homogeneous catalysed amination of alcohols |
CA2844588A1 (en) * | 2011-08-10 | 2013-02-14 | Merck Patent Gmbh | Pyrido-pyrimidine derivatives |
WO2014022117A1 (en) | 2012-07-28 | 2014-02-06 | Calitor Sciences, Llc | Substituted pyrazolone compounds and methods of use |
US8975282B2 (en) | 2012-07-28 | 2015-03-10 | Sunshine Lake Pharma Co., Ltd. | Substituted pyrazolone compounds and methods of use |
EP2953933A1 (en) * | 2013-02-07 | 2015-12-16 | Merck Patent GmbH | Substituted acetylene derivatives and their use as positive allosteric modulators of mglur4 |
CN108701171B (zh) * | 2015-10-22 | 2022-06-10 | 马古苏托科技大学 | 在通过抑制cyp17a1和cyp19a1治疗癌症中具有应用的药效团、化合物和方法 |
WO2018172852A1 (en) * | 2017-03-21 | 2018-09-27 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same |
KR102229471B1 (ko) * | 2018-05-31 | 2021-03-18 | 주식회사 씨앤드씨신약연구소 | 헤테로사이클 유도체 및 그의 용도 |
AU2019416117B2 (en) | 2018-12-28 | 2024-05-02 | Deciphera Pharmaceuticals, Llc | CSF1R inhibitors for use in treating cancer |
CN116462677A (zh) * | 2022-01-20 | 2023-07-21 | 上海和誉生物医药科技有限公司 | 一种多稠环prmt5抑制剂及其制备方法和应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
US6184225B1 (en) | 1996-02-13 | 2001-02-06 | Zeneca Limited | Quinazoline derivatives as VEGF inhibitors |
AU719327B2 (en) | 1996-03-05 | 2000-05-04 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
PL359181A1 (en) | 2000-07-07 | 2004-08-23 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
AU3652102A (en) | 2000-12-01 | 2002-06-11 | Guilford Pharm Inc | Compounds and their uses |
-
2009
- 2009-02-25 US US12/919,136 patent/US8735584B2/en not_active Expired - Fee Related
- 2009-02-25 EP EP09713744A patent/EP2254889B1/en not_active Not-in-force
- 2009-02-25 AU AU2009219376A patent/AU2009219376B2/en not_active Ceased
- 2009-02-25 ES ES09713744T patent/ES2401550T3/es active Active
- 2009-02-25 WO PCT/US2009/035089 patent/WO2009108670A1/en active Application Filing
- 2009-02-25 CA CA2712990A patent/CA2712990C/en not_active Expired - Fee Related
- 2009-02-25 JP JP2010548836A patent/JP5529761B2/ja not_active Expired - Fee Related
- 2009-02-25 CN CN2009801054114A patent/CN101952287B/zh not_active Expired - Fee Related
- 2009-02-27 AR ARP090100694A patent/AR070540A1/es active IP Right Grant
-
2010
- 2010-08-04 IL IL207415A patent/IL207415A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
AU2009219376A1 (en) | 2009-09-03 |
JP5529761B2 (ja) | 2014-06-25 |
CA2712990C (en) | 2016-09-27 |
AU2009219376B2 (en) | 2014-09-25 |
CA2712990A1 (en) | 2009-09-03 |
US20110053906A1 (en) | 2011-03-03 |
IL207415A0 (en) | 2010-12-30 |
EP2254889A1 (en) | 2010-12-01 |
US8735584B2 (en) | 2014-05-27 |
ES2401550T3 (es) | 2013-04-22 |
WO2009108670A1 (en) | 2009-09-03 |
EP2254889B1 (en) | 2012-12-19 |
JP2011513322A (ja) | 2011-04-28 |
CN101952287A (zh) | 2011-01-19 |
CN101952287B (zh) | 2013-11-27 |
IL207415A (en) | 2016-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR070540A1 (es) | Derivados de 6-oxo-5, 6-dihidro-benzo[c][1, 8]naftiridina, un proceso para su preparacion, un kit que los incluye y su uso en la fabricacion de medicamentos para el tratamiento del cancer. | |
AR066543A1 (es) | Derivados de piridazinona | |
AR056327A1 (es) | Compuestos de nucleosidos para el tratamiento de infecciones virales | |
PE20090060A1 (es) | ANALOGOS DE IMIDAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE PI3 CINASA Y mTOR | |
AR066892A1 (es) | Derivados de benzoxazolona, proceso, medicamento, uso para tratar tumores y kit | |
MX9203122A (es) | Compuestos analogos de distamicina a y composiciones farmaceuticas que los contienen. | |
AR056979A1 (es) | Derivados de dihidrobenzofuranos y usos de los mismos | |
AR062050A1 (es) | Derivados de amina utiles como agentes anti-cancerigenos | |
AR068657A1 (es) | Derivados de piperidina y piperazina | |
AR057214A1 (es) | Derivados de piridazinona como inhibidores, reguladores o moduladores de quinasas. | |
AR063804A1 (es) | Compuestos de azoniabiciclo[2.2.2]octano | |
AR055041A1 (es) | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. | |
AR071208A1 (es) | Derivados de piridazinona | |
SV2010003464A (es) | Derivados de pirimida utiles para el tratamiento de condiciones inflamatorias o alergicas | |
WO2008080986A1 (en) | Furan derivatives, method of synthesis and uses thereof | |
EA200970582A1 (ru) | ПРОИЗВОДНЫЕ 5-[4-(АЗЕТИДИН-3-ИЛОКСИ)ФЕНИЛ]-2-ФЕНИЛ-5Н-ТИАЗОЛО[5,4-c]ПИРИДИН-4-ОНА И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ РЕЦЕПТОРОВ MCH | |
AR075122A1 (es) | Derivados de piridazinona | |
AR058398A1 (es) | Diazepinonas, procesos de obtencion , composiciones farmaceuticas y su uso como inhibidores de quinasas. | |
AR048573A1 (es) | Compuesto de 8-azoniabiciclo[3.2.1]octano sustituido en la posicion 3, composicion farmceutica que lo comprende y su uso para preparar esta ultima | |
PE20240886A1 (es) | Compuestos espirociclicos | |
AR071217A1 (es) | Derivados bencimidazol | |
MY129329A (en) | 6,7-DIHYDRO-5H-PYRAZOLO[1,2-a]PYRAZOL-1-ONES WHICH CONTROL INFLAMMATORY CYTOKINES | |
US4125547A (en) | 12,13(E)-Didehydro-13,14-dihydro-9-deoxy-PGD1 compounds | |
EA200701035A1 (ru) | Замещенные n-сульфониламинобензил-2-феноксиацетамидные соединения | |
AR045810A1 (es) | 6-[fenil (sustituidas) ] triazolopirimidinas como agentes anticancerosos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |